BackBristol-Myers Squibb Overview
Bristol-Myers Squibb Co.

Bristol-Myers Squibb Target Price

See Bristol-Myers Squibb's analyst price targets ($70) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$63.06

Average Target Price

$70.0011% upside

8 analysts in the last 4 months

High: $82 | Low: $59

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-09-16Piper Sandler$8230% upsideOpen
2026-09-10HSBC$653.1% upsideOpen
2026-08-05Roth Capital$7518.9% upsideOpen
2026-08-05Argus ResearchJasper Hellweg$7518.9% upsideOpen
2026-08-04RBC CapitalTrung Huynh$641.5% upsideOpen
2026-07-31Cantor FitzgeraldCarter Gould$596.4% downsideOpen
2026-07-31GuggenheimSeamus Fernandez$7518.9% upsideOpen
2026-07-31Wells Fargo$653.1% upsideOpen
2026-04-08Cantor Fitzgerald$5414.4% downsideOpen
2026-03-06UBSMichael Yee$7011% upsideOpen
2026-02-24RBC CapitalTrung Huynh$604.9% downsideOpen
2026-02-23Piper Sandler$7518.9% upsideOpen
2026-02-19Barclays$7518.9% upsideOpen
2026-02-06Morgan StanleyTerence Flynn$4036.6% downsideOpen
2026-02-06Guggenheim$7214.2% upsideOpen
2026-02-06Wells FargoMohit Bansal$604.9% downsideOpen
2026-01-28Piper Sandler$664.7% upsideOpen
2026-01-13Leerink PartnersDavid Risinger$604.9% downsideOpen
2026-01-09ScotiabankLouise Chen$604.9% downsideOpen
2026-01-07UBS$653.1% upsideOpen
2025-12-12Morgan Stanley$3741.3% downsideOpen
2025-12-12Guggenheim$621.7% downsideOpen
2025-12-10HSBC$5316% downsideOpen
2025-12-04ScotiabankLouis Chen$5316% downsideOpen
2025-12-03Truist FinancialSrikripa Devarakonda$653.1% upsideOpen
2025-08-05DaiwaNarumi Nakagiri$4233.4% downsideOpen
2025-07-21Truist FinancialDavid Macdonald$8433.2% upsideOpen
2025-04-23JefferiesAkash Tewari$687.8% upsideOpen
2025-04-22Piper SandlerDavid Amsellem$653.1% upsideOpen
2024-11-12BMO CapitalEvan Seigerman$613.3% downsideOpen
2024-11-01BMO CapitalEvan David Seigerman$579.6% downsideOpen
2024-09-23BMO CapitalEvan David Seigerman$4823.9% downsideOpen
2024-07-29Goldman SachsChris Shibutani$579.6% downsideOpen
2024-07-29BarclaysCarter Gould$4135% downsideOpen
2024-07-12UBSTrung Huynh$4331.8% downsideOpen
2024-05-16Cowen & Co.Steve Scala$676.2% upsideOpen
2024-01-30Deutsche BankJames Shin$5512.8% downsideOpen
2023-11-27BMO CapitalEvan Seigerman$604.9% downsideOpen
2023-10-12Leerink PartnersDavid Risinger$664.7% upsideOpen
2023-09-06Cantor FitzgeraldLouise Chen$7518.9% upsideOpen
2022-05-18Wells FargoMohit Bansal$7011% upsideOpen
2022-05-02BMO Capital$9245.9% upsideOpen
2022-05-02Barclays$687.8% upsideOpen
2022-05-02GuggenheimSeamus Fernandez$8026.9% upsideOpen
2022-05-02BMO CapitalEvan Seigerman$8738% upsideOpen
2022-04-11Morgan StanleyTerence Flynn$641.5% upsideOpen
2022-04-04BMO CapitalEvan Seigerman$8128.4% upsideOpen
2022-03-28Morgan StanleyMatthew Harrison$664.7% upsideOpen
2022-03-17BMO CapitalEvan David Seigerman$7417.3% upsideOpen
2021-10-28BarclaysCarter Gould$664.7% upsideOpen

Bristol-Myers Squibb (BMY) FAQ

Bristol-Myers Squibb posts a target price of $70. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $70 for BMY means covering analysts, on average, see the stock 11.0% upside of $63.06 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for BMY's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Bristol-Myers Squibb's other metric pages and overview cover the third.

Judging Bristol-Myers Squibb against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $70 here, then scan peer and history charts to see if the gap is persistent.